How are we coping with the pandemic?

Team Veye | 21-Sep-2020 coping with the pandemic

The world is in the midst of a COVID-19 pandemic. WHO and partners are working together on the response needed and are racing to find a vaccine.

Although scientists world over are trying to produce an effective coronavirus vaccine at the earliest, it is not expected to be reaching clinics too soon.

The work to decipher the COVID-19 started in January 2020, but the vaccine safety trials began only in March. The vaccine testing process takes much longer and goes through the various phases of preclinical testing to efficacy trials. Then these have to seek early or limited approval/approval. The final approval is accorded by the regulators only after reviewing the trial results. 

There are currently over 169 COVID-19 vaccine candidates under development, with 26 of these in the human trial phase. At present, we do not have any vaccines approved for full use.

The country is fighting the pandemic on many fronts. Apart from employment related and economic stimulus measures, strong steps have been taken to ease the lockdown.

With some federal measures, many state level restrictions are also in force. A travel ban is in place that prevents all non-Australian citizens and non-residents from entering Australia. Interstate travel from Victoria is restricted to essential workers and hotel quarantine applies on arrival. Travel to South Australia, Queensland, and the Northern Territory is also restricted and borders are effectively ‘closed’ in Tasmania and Western Australia. 

Restrictions are now being eased across the country on a state and territory basis depending on local epidemiology, except for the state of Victoria which is under Stage 4 restrictions. 

While Victorian businesses are only allowed to operate onsite if they are a ‘permitted premises’, a roadmap for reopening has been announced that some restrictions will be eased from 28 September in the state of Victoria.


Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website, and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.

veye logo

Grab Your Free Report On 5 ASX Dividend Stocks To Buy In 2024